Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

March 31, 2017

Conditions
Obesity
Interventions
DRUG

Elonva

"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years."

Trial Locations (1)

1000

Division of gynecology, Department of human reproduction, Ljubljana

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Medical Centre Ljubljana

OTHER

NCT02606500 - Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success | Biotech Hunter | Biotech Hunter